| Literature DB >> 28560717 |
Veli-Pekka Harjola1, Wilfried Mullens2,3, Marek Banaszewski4, Johann Bauersachs5, Hans-Peter Brunner-La Rocca6, Ovidiu Chioncel7, Sean P Collins8, Wolfram Doehner9,10, Gerasimos S Filippatos11, Andreas J Flammer12, Valentin Fuhrmann13,14, Mitja Lainscak15,16,17, Johan Lassus18, Matthieu Legrand19,20,21, Josep Masip22,23, Christian Mueller24,25, Zoltán Papp26, John Parissis11, Elke Platz27, Alain Rudiger28, Frank Ruschitzka12, Andreas Schäfer5, Petar M Seferovic29,30, Hadi Skouri31, Mehmet Birhan Yilmaz32, Alexandre Mebazaa19,20,33,34.
Abstract
Organ injury and impairment are commonly observed in patients with acute heart failure (AHF), and congestion is an essential pathophysiological mechanism of impaired organ function. Congestion is the predominant clinical profile in most patients with AHF; a smaller proportion presents with peripheral hypoperfusion or cardiogenic shock. Hypoperfusion further deteriorates organ function. The injury and dysfunction of target organs (i.e. heart, lungs, kidneys, liver, intestine, brain) in the setting of AHF are associated with increased risk for mortality. Improvement in organ function after decongestive therapies has been associated with a lower risk for post-discharge mortality. Thus, the prevention and correction of organ dysfunction represent a therapeutic target of interest in AHF and should be evaluated in clinical trials. Treatment strategies that specifically prevent, reduce or reverse organ dysfunction remain to be identified and evaluated to determine if such interventions impact mortality, morbidity and patient-centred outcomes. This paper reflects current understanding among experts of the presentation and management of organ impairment in AHF and suggests priorities for future research to advance the field.Entities:
Keywords: Heart failure; Multiple organ failure; Venous congestion
Mesh:
Year: 2017 PMID: 28560717 PMCID: PMC5734941 DOI: 10.1002/ejhf.872
Source DB: PubMed Journal: Eur J Heart Fail ISSN: 1388-9842 Impact factor: 15.534